---
schema_version: "secwatch.filing_event.v1"
accession: "0001477449-24-000017"
form_type: "8-K"
ticker: "TDOC"
cik: "0001477449"
company_name: "Teladoc Health, Inc."
filed_at: "2024-02-20T23:59:59+00:00"
generated_at: "2026-06-05T23:01:00.423754+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teladoc Q4 2023 revenue $660.5M, adj. EBITDA up 22% to $114.4M; guides FY2024 revenue $2.64-2.74B

## Summary
- Q4 revenue $660.5M (+4% YoY); Full year revenue $2,602.4M (+8% YoY).
- Q4 net loss $28.9M ($0.17/sh) vs $3.81B loss a year ago; FY net loss $220.4M ($1.34/sh).
- Q4 adjusted EBITDA $114.4M (+22% YoY); FY adj. EBITDA $328.1M (+33% YoY); FY free cash flow $193.7M.
- FY2024 guidance: revenue $2,635-2,735M, adj. EBITDA $350-390M, free cash flow $210-240M.
- Efficiency program targets ~$43M net expense reduction in 2024; expects $85M annualized savings.

## SEC filing metadata
- accession: 0001477449-24-000017
- form_type: 8-K
- ticker: TDOC
- cik: 0001477449
- company_name: Teladoc Health, Inc.
- filed_at: 2024-02-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000017/0001477449-24-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000017/tdoc-20240220.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477449-24-000017
- JSON: https://secwatch.observer/filing/0001477449-24-000017.json
- Plain text: https://secwatch.observer/filing/0001477449-24-000017.txt

## Key facts
- Earnings Releases
  Teladoc Health, Inc. reported the full year ended December 31, 2023 results: revenue $2,602.4 million, net income $220.4 million, EPS $1.34 per share. Guidance initiated.
  - Period: the full year ended December 31, 2023
  - Revenue: $2,602.4 million
  - Net income: $220.4 million
  - EPS: $1.34 per share
  - Guidance: initiated
  - Result: reported results
  source text: Teladoc Health Reports Fourth Quarter and Full Year 2023 Results • Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million • Fourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000017/0001477449-24-000017-index.htm
- Earnings Releases
  Teladoc Health, Inc. reported the fourth quarter of 2023 results: revenue $660.5 million, net income $28.9 million, EPS $0.17 per share. Guidance initiated.
  - Period: the fourth quarter of 2023
  - Revenue: $660.5 million
  - Net income: $28.9 million
  - EPS: $0.17 per share
  - Guidance: initiated
  - Result: reported results
  source text: $ (84.60) 98 % Adjusted EBITDA (1) $ 114,443 $ 94,094 22 % $ 328,120 $ 246,513 33 % See note (1) in the Notes section that follows. 1 Fourth Quarter 2023 Revenue increased 4% to $660.5 million from $637.7 million in the fourth quarter of 2022. Access fees revenue grew 4% to $573.9 million and other revenue grew 3% to $86.6 million. U.S. revenue grew 2% to $564.8
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000017/0001477449-24-000017-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.